Program
seladelpar
Also written as “Seladelpar”, “MBX-8025” and “Seladelpar 10 mg”.
Its studies are mostly in Liver Cirrhosis, Biliary · Cholangitis, Sclerosing · Non-alcoholic Fatty Liver Disease · Homozygous Familial Hypercholesterolemia · Hyperlipidemias, led by Gilead Sciences.
Furthest: phase 3, since Sep 26, 201714 company-led studies, 3 open or runningNext primary completion: Nov 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 143 open or running | phase 3since Sep 26, 2017 | Jun 17, 2008 | Nov 2028phase 3 · NCT03301506 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 17, 2008First study: phase 2 study in HyperlipidemiasFirst studyNCT00701883 · 183 enrolled · United States
- May 22, 2015Phase 2 study in Homozygous Familial HypercholesterolemiaNCT02472535 · 13 enrolled · Canada, France, Netherlands and more
- Nov 13, 2015Phase 2 study in Liver Cirrhosis, BiliaryNCT02609048 · 41 enrolled · United States, Canada, Germany and more
- Nov 2, 2016Phase 2 study in Liver Cirrhosis, BiliaryNCT02955602 · 119 enrolled · United States, Canada, Germany and more
- Sep 26, 2017Phase 3 study in Liver Cirrhosis, BiliaryNCT03301506 · 340 enrolled · United States, Argentina, Australia and more
- Nov 16, 2017Phase 1 study in Hepatic ImpairmentNCT03369002 · 32 enrolled · United States
- May 9, 2018Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03551522 · 181 enrolled · United States
- Jul 18, 2018Phase 3 study in Liver Cirrhosis, BiliaryNCT03602560 · 265 enrolled · United States, Argentina, Australia and more
- Jun 20, 2019Phase 2 study in Cholangitis, SclerosingNCT04024813 · 1 enrolled · United States, Canada, Poland
- Nov 4, 2020Phase 3 study in Liver Cirrhosis, BiliaryNCT04620733 · 193 enrolled · United States, Argentina, Australia and more
- Jun 14, 2021Phase 1 study in Liver Cirrhosis, BiliaryNCT04950764 · 24 enrolled · United States, South Korea, Spain and more
- Sep 18, 20232 phase 3 studies in Liver Cirrhosis, BiliaryNCT06051617, NCT06060665
- Sep 21, 2026Phase 2 study in Liver Cirrhosis, BiliaryNCT07841977 · 132 planned · United States
- Oct 27, 2026Primary completion moved from 2028-06 to 2028-12Date moved laterphase 2 · +6 months · NCT07841977
Ahead
- Nov 2028Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT03301506
- Dec 2028Primary completion: phase 2 study in Liver Cirrhosis, BiliaryNCT07841977
- Aug 2030Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT06051617
TargetBeta
“An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-delta (PPARd), with bile acids reducing activity”NCIt, by rule
“Peroxisome proliferator-activated receptor delta agonist; Peroxisome proliferator-activated receptor delta agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07841977Liver Cirrhosis, Biliary · United States | 2 | Recruiting | Dec 2028 | 132 |
| NCT06060665Liver Cirrhosis, Biliary · United States, Canada | 3 | Completed | May 6, 2026 | 96 |
| NCT06051617Liver Cirrhosis, Biliary · United States, Argentina, Australia and more | 3 | Recruiting | Aug 2030 | 402 |
| NCT04950764Liver Cirrhosis, Biliary · United States, South Korea, Spain and more | 1 | Completed | Feb 24, 2025 | 24 |
| NCT04620733Liver Cirrhosis, Biliary · United States, Argentina, Australia and more | 3 | Completed | Aug 11, 2023 | 193 |
| NCT04024813Cholangitis, Sclerosing · United States, Canada, Poland | 2 | Terminated | Jan 9, 2020 | 1 |
| NCT03602560Liver Cirrhosis, Biliary · United States, Argentina, Australia and more | 3 | Completed | Feb 16, 2020 | 265 |
| NCT03551522Non-alcoholic Fatty Liver Disease · United States | 2 | Terminated | May 8, 2019 | 181 |
| NCT03369002Hepatic Impairment · United States | 1 | Completed | May 15, 2018 | 32 |
| NCT03301506Liver Cirrhosis, Biliary · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 2028 | 340 |
| NCT02955602Liver Cirrhosis, Biliary · United States, Canada, Germany and more | 2 | Completed | Sep 7, 2018 | 119 |
| NCT02609048Liver Cirrhosis, Biliary · United States, Canada, Germany and more | 2 | Terminated | Jul 1, 2016 | 41 |
| NCT02472535Homozygous Familial Hypercholesterolemia · Canada, France, Netherlands and more | 2 | Completed | Feb 2016 | 13 |
| NCT00701883Hyperlipidemias · United States | 2 | Completed | Aug 2008 | 183 |
How it is read
Names in the registry
- “Seladelpar”, 5 entries
- “MBX-8025”, 4 entries
- “Seladelpar 10 mg”, 2 entries
- “Seladelpar 5 mg Capsule”, 1 entry
- “Seladelpar 10 mg Capsule”, 1 entry
Conditions, from the studies’ own filings
- Liver Cirrhosis, Biliary, 9 studies
- Cholangitis, Sclerosing, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
- Homozygous Familial Hypercholesterolemia, 1 study
- Hyperlipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.